Retatrutide: The Triple-Agonist Peptide Making Headlines

Retatrutide is generating serious buzz in the peptide research world. Developed by Eli Lilly, it’s a first-in-class triple receptor agonist – meaning it targets three metabolic pathways instead of one or two. The clinical trial results so far have been impressive.

What Is Retatrutide?

Retatrutide (LY3437943) is a 39-amino acid peptide that activates three key receptors:

• GLP-1 – Controls appetite and slows digestion
• GIP – Boosts insulin response and influences fat metabolism
• Glucagon – Increases energy expenditure and fat burning

It has a half-life of about 6 days, allowing for once-weekly dosing. Retatrutide targets all three – that’s the key difference.

How Does It Work?

The triple-agonist approach works from multiple angles: it reduces how much you eat (via GLP-1 and GIP) while increasing how many calories your body burns (via glucagon). This combination of eating less and burning more is what researchers believe drives Retatrutide’s strong results in trials.

What the Research Shows

Clinical trials have produced striking results:

• Phase 2 Trial (48 weeks): Participants saw an average weight reduction of up to 24% of body weight
• Phase 3 TRIUMPH-4 (68 weeks): Adults with obesity and knee osteoarthritis lost up to 29% of body weight – an average of 71.2 lbs at the highest dose
• Knee Pain Relief: WOMAC pain scores dropped by up to 75.8%, with more than 1 in 8 participants becoming completely free of knee pain
• Liver Fat: A separate study showed up to 82% reduction in liver fat content

How It Compares